Clinical trial
Differentiation Induction in Acute Myelogenous Leukemia
NCT00175812 · University of Bergen, Other · Completed
Key facts
| NCT number | NCT00175812 |
|---|---|
| Title | Differentiation Induction in Acute Myelogenous Leukemia |
| Official title | Differentiation Induction Therapy for Acute Myelogenous Leukemia |
| Lead sponsor | University of Bergen, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | all-trans retinoic acid (ATRA), Valproic acid, Theophyllin |
| Enrollment | 24 |
| Start date | Nov 1, 2004 |
| Primary completion | May 1, 2008 |
| Completion | Nov 1, 2009 |
| First posted | Sep 15, 2005 |
| Last update posted | Jun 24, 2015 |
| Countries | Norway |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: